GenomOncology to Present at Cleveland Clinic Medical Innovation Summit
News Oct 25, 2014
GenomOncology has announced that Manuel Glynias, the company’s President and CEO, will be presenting a corporate overview at the Cleveland Clinic’s 2014 Medical Innovation Summit to be held October 26-29 in Cleveland, IL.
The presentation will take place on Wednesday October 29 at 8:25 ET at the Cleveland Convention Center in Room 26. There will be a breakout for Q&A immediately following the presentation in Room 23.
GenomOncology is focused on enabling precision medicine by translating next generation sequencing data into actionable information for clinicians and researchers. The company’s proprietary technology platform, GO Clinical Workbench, streamlines the use of NGS data in conjunction with other analytic modalities and allows clinical laboratories to produce an actionable clinical report using the molecular profile of an individual patient’s tumor.
“I was pleased to be invited to participate in the Cleveland Clinic’s Medical Innovation Summit,” commented Manuel Glynias. “Translating the vast amounts of data from next-generation sequencing into useful information for clinical use is of the utmost importance. GenomOncology is dedicated to expanding the availability of this information to the industry and welcomes the opportunity to share ideas with conference attendees.”
Mr. Glynias is a serial entrepreneur with over 25 years of experience in bioinformatics. Immediately prior to GenomOncology, Manuel was a partner at Rosetta, a leading interactive marketing agency, where he helped develop big data solutions for ecommerce clients.
In the late 90’s, Manuel was the founder and CEO of NetGenics, a venture-backed provider of discovery informatics to the biopharmaceutical industry and academic research centers. He also developed a number of other commercial software platforms including MacGene, Gene Works, and Primer Express. Manuel has an AB in Biochemistry and Molecular Biology from Harvard College.
Changing Lanes: Algorithm Helps AI Drive More Like HumansNews
For self-driving cars, algorithms for changing lanes are beset by one of two problems. Either, they rely on detailed statistical models of the driving environment, which are too complex to analyze on the fly; or they’re so simple that they can lead to impractically conservative decisions, such as never changing lanes at all. Now a new algorithm hopes to split the difference, allowing aggressive lane changes than the simple models do but relies only on immediate information about other vehicles’ directions and velocities to make decisions.
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE
Faulty Gene Leads to Alcohol-Induced Heart FailureNews
A faulty gene interacts with alcohol to accelerate heart failure in susceptible patients, a study suggests. This dangerous interaction can occur even when only moderate amounts of alcohol have been consumed.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018